Information: This is an outdated version of the data model. You can find a Versions overview via Versions on the left. You can find the newest Version by clicking here.
Information:
Error:
ID
34386
Description
Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver; ODM derived from: https://clinicaltrials.gov/show/NCT01501240
Link
https://clinicaltrials.gov/show/NCT01501240
Keywords
Versions (2)
- 1/17/19 1/17/19 -
- 5/14/19 5/14/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 17, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Liver Cirrhosis NCT01501240
Eligibility Liver Cirrhosis NCT01501240
- StudyEvent: Eligibility
Similar models
Eligibility Liver Cirrhosis NCT01501240
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
patients with known liver cirrhosis based on either histology, or a combination of physical examination, laboratory tests, and imaging data
boolean
ID.2
Item
patients with known liver cirrhosis based on either histology, or a combination of physical examination, laboratory tests, and imaging data
boolean
ID.3
Item
patients under 20 years of age
boolean
ID.4
Item
patients who have more than 10 nodules detected on hepatobiliary phase of gadoxetic acid-enhanced mr
boolean
ID.5
Item
patients who underwent transarterial chemotherapy or radiofrequency ablation
boolean
ID.6
Item
women who are pregnant, lactating or who are of childbearing potential
boolean
ID.7
Item
patients with any physical or mental status than interferes with the signing of informed consent
boolean
ID.8
Item
patients with a contraindication for mr
boolean
ID.9
Item
patients with impaired renal function (e.g. acute renal failure or egfr < 30 ml/min/1.73m2) or patients on dialysis
boolean